Next Article in Journal
Olive Oil Industry By-Products as a Novel Source of Biophenols with a Promising Role in Alzheimer Disease Prevention
Previous Article in Journal
Bio-Based Self-Healing Epoxy Vitrimers with Dynamic Imine and Disulfide Bonds Derived from Vanillin, Cystamine, and Dimer Diamine
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 20
10.3390/molecules29204840
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Molecules 2022, 27(21), 7524.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524

by
Dongxiao Fan
1,2,
Chenshu Liu
1,2,
Zhongyu Zhang
3,4,
Kan Huang
1,2,
Tengyao Wang
3,4,
Sifan Chen
3,4 and
Zilun Li
1,2,*
1
Division of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2
National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
4
Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(20), 4840; https://doi.org/10.3390/molecules29204840
Submission received: 7 December 2022 / Accepted: 11 June 2024 / Published: 12 October 2024
Versions Notes
Text Correction
  • Figure 1 of the original publication [1]: the figure legend “PPARα: peroxisome proliferator-activated receptor-gamma coactivator-1α” should be “PPARα: peroxisome proliferator-activated receptor α”.
  • Original: PPARα: peroxisome proliferator-activated receptor-gamma coactivator-1α.
  • Correction: PPARα: peroxisome proliferator-activated receptor α.
  • The fourth paragraph of Section 2.1 in the original publication, “peroxisome proliferator-activated receptor-gamma coactivator-1α (PPARα)” should be “peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α)”.
  • Original: peroxisome proliferator-activated receptor-gamma coactivator-1α (PPARα).
  • Correction: peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α).
  • In the final paragraph of Section 2.2, “SIRT1-mediated activation of PPARα and its coactivator peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α)” should be “SIRT1-mediated activation of peroxisome proliferator-activated receptor α (PPARα) and its coactivator PGC1α”.
  • Original: SIRT1-mediated activation of PPARα and its coactivator peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α).
  • Correction: SIRT1-mediated activation of peroxisome proliferator-activated receptor α (PPARα) and its coactivator PGC1α.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Fan, D.; Liu, C.; Zhang, Z.; Huang, K.; Wang, T.; Chen, S.; Li, Z. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Fan, D.; Liu, C.; Zhang, Z.; Huang, K.; Wang, T.; Chen, S.; Li, Z. Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524. Molecules 2024, 29, 4840. https://doi.org/10.3390/molecules29204840

AMA Style

Fan D, Liu C, Zhang Z, Huang K, Wang T, Chen S, Li Z. Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524. Molecules. 2024; 29(20):4840. https://doi.org/10.3390/molecules29204840

Chicago/Turabian Style

Fan, Dongxiao, Chenshu Liu, Zhongyu Zhang, Kan Huang, Tengyao Wang, Sifan Chen, and Zilun Li. 2024. "Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524" Molecules 29, no. 20: 4840. https://doi.org/10.3390/molecules29204840

APA Style

Fan, D., Liu, C., Zhang, Z., Huang, K., Wang, T., Chen, S., & Li, Z. (2024). Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524. Molecules, 29(20), 4840. https://doi.org/10.3390/molecules29204840

Article Metrics

Back to TopTop